What is PTC Therapeutics's return on equity?

PTC Therapeutics (PTCT) reported return on equity of -216.7% in Q4 2021.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

PTC Therapeutics PTCT Return on equity

Discontinued — last reported Q4 '21

Return on equity at other companies

BioMarin PharmaceuticalsBMRN

9.1%+2.8pp

ALN

Alnylam PharmaceuticalsALNY

66.9%—

Arrowhead ResearchARWR

-46.4%+341pp

United TherapeuticsUTHR

20.3%+0.3pp

BiogenBIIB

8%-1.2pp

Protagonist TherapeuticsPTGX

-17.1%-26.1pp

Other financials

Income statement

See full

Revenue$272.6M-76.8%

Operating income$45.0M-95.4%

Net income-$2.8M-100%

EPS (diluted)-$0.03-100%

Balance sheet

See full

Cash & equivalents$834.0M-43.7%

Total debt$395.1M+0.1%

Total equity-$180.5M+2.9%

Total assets$2.9B+8.0%

Cash flow

See full

Operating cash flow-$59.0M-107%

CapEx$1.2M-30.6%

Free cash flow-$60.2M-107%

Valuation

See full

Market cap$6.55B+40.3%

Enterprise value$6.11B+77.3%

P/E8×—

P/S7.9×+5.3×

Profitability

See full

Gross margin96%—

Operating margin1.6%-38.7pp

Net margin42.3%+27.4pp

FCF margin39.1%+32.8pp

Returns & leverage

See full

Debt / equity372.3×—

Current ratio2.4×-1.5×

Where this comes from

Calculated from PTC Therapeutics’s reported figures.

net income/total stockholders equity=-216.7%

Based on trailing twelve months.

The official record: PTC Therapeutics’s 10-K, filed February 21, 2023, on SEC EDGAR. View the filing →

Ask your AI about PTC Therapeutics's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is PTC Therapeutics's return on equity?: PTC Therapeutics (PTCT) reported return on equity of -216.7% in Q4 2021.
What does return on equity mean?: Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.